| P2093 | author name string | John Yoo | |
| | Eric Winquist | |
| | Kevin Fung | |
| | Lorne S Parnes | |
| | Varagur Venkatesan | |
| | Jason Franklin | |
| | Denise Lewis | |
| | Douglas Angel | |
| | Scott J Hamilton | |
| P2860 | cites work | Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer | Q30486848 |
| | Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. | Q30591228 |
| | Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer | Q33377142 |
| | Application of antioxidants and other agents to prevent cisplatin ototoxicity | Q33777748 |
| | Intratympanic steroids for inner ear disorders: a review | Q35013597 |
| | Comparison of five agents in protecting the cochlea against the ototoxic effects of cisplatin in the hamster | Q36891791 |
| | Clinical pharmacokinetics of N-acetylcysteine | Q37713718 |
| | Intravenous acetylcysteine for the treatment of acetaminophen overdose | Q37815203 |
| | Cisplatin rescue therapy: experience with sodium thiosulfate, WR2721, and diethyldithiocarbamate | Q37903232 |
| | Acetaminophen and acetylcysteine dose and duration: past, present and future. | Q37982762 |
| | Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. | Q38490567 |
| | Concurrent chemoradiotherapy in the management of squamous cell cancer of the oropharynx: current standards and future directions | Q40163496 |
| | Cisplatin-induced ototoxicity: the effect of pigmentation and inhibitory agents | Q40892797 |
| | Cisplatin-induced ototoxicity: audiometric findings and experimental cochlear pathology | Q42436551 |
| | Effect of 4-methylthiobenzoic acid on cisplatin-induced ototoxicity in the rat. | Q42472901 |
| | D-Methionine protects against cisplatin damage to the stria vascularis | Q42480391 |
| | Effects of alpha-tocopherol on cisplatin-induced ototoxicity in guinea pigs | Q42497488 |
| | Round window application of D-methionine provides complete cisplatin otoprotection | Q42522966 |
| | D-methionine provides excellent protection from cisplatin ototoxicity in the rat. | Q42527795 |
| | Differential damage to auditory neurons and hair cells by ototoxins and neuroprotection by specific neurotrophins in rat cochlear organotypic cultures | Q42552469 |
| | Round window membrane delivery of L-methionine provides protection from cisplatin ototoxicity without compromising chemotherapeutic efficacy | Q43639242 |
| | L-n-acetyl-cysteine protection against cisplatin-induced auditory neuronal and hair cell toxicity | Q43745674 |
| | 4-Methylthiobenzoic acid reduces cisplatin nephrotoxicity in rats without compromising anti-tumour activity. | Q43917100 |
| | Round window application of D-methionine, sodium thiosulfate, brain-derived neurotrophic factor, and fibroblast growth factor-2 in cisplatin-induced ototoxicity | Q44729016 |
| | Protection against cisplatin-induced ototoxicity by N-acetylcysteine in a rat model | Q44952944 |
| | Prevention of cisplatin ototoxicity using transtympanic N-acetylcysteine and lactate | Q45152818 |
| | Changes in the stria vascularis of the guinea pig due to cis-platinum | Q46264909 |
| | Protection against cisplatin-induced toxicities by N-acetylcysteine and sodium thiosulfate as assessed at the molecular, cellular, and in vivo levels | Q46542133 |
| | Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer | Q46932585 |
| | Introduction to sample size determination and power analysis for clinical trials | Q47281427 |
| | Transtympanic injections of N-acetylcysteine for the prevention of cisplatin-induced ototoxicity: a feasible method with promising efficacy | Q48208401 |
| | cis-platinum ototoxicity in children | Q48661276 |
| | Ototoxic protection of sodium thiosulfate: daily vs constant infusion. | Q50479115 |
| | Local application of sodium thiosulfate prevents cisplatin-induced hearing loss in the guinea pig. | Q50482976 |
| | Ototoxicity caused by cisplatin is ameliorated by melatonin and other antioxidants. | Q50497431 |
| | Mechanism of cisplatin ototoxicity: antioxidant system. | Q50519742 |
| | Cisplatin: evaluation of its ototoxic potential. | Q53744914 |
| | Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. | Q53794992 |
| | High-dose cisplatin in patients with advanced malignancies. | Q53855067 |
| | Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck | Q56532861 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cisplatin | Q412415 |
| | head and neck cancer | Q1783924 |
| | head and neck carcinoma | Q18554836 |
| | neck cancer | Q18966654 |
| P304 | page(s) | E87-94 | |
| P577 | publication date | 2013-10-01 | |
| P1433 | published in | The Laryngoscope | Q15755068 |
| P1476 | title | Cisplatin otoprotection using transtympanic L-N-acetylcysteine: a pilot randomized study in head and neck cancer patients | |
| P478 | volume | 124 | |